Determine the necessary mass, volume, or concentration for preparing a solution.
This is a demo store. No orders will be fulfilled.
| SKU | Size | Availability |
Price | Qty |
|---|---|---|---|---|
|
I649000-5mg
|
5mg |
Available within 8-12 weeks(?)
Production requires sourcing of materials. We appreciate your patience and understanding.
|
$1,050.90
|
|
|
I649000-10mg
|
10mg |
Available within 8-12 weeks(?)
Production requires sourcing of materials. We appreciate your patience and understanding.
|
$1,650.90
|
|
| Specifications & Purity | ≥98% |
|---|---|
| Biochemical and Physiological Mechanisms | IV-361 is an orally active and selective CDK7 inhibitor ( K i ≤50 nM). IV-361 has anti-cancer activity (US20190256531A1). |
| Storage Temp | Store at -20°C |
| Shipped In |
Ice chest + Ice pads This product requires cold chain shipping. Ground and other economy services are not available. |
| Product Description |
IV-361 is an orally active and selective CDK7 inhibitor ( K i ≤50 nM). IV-361 has anti-cancer activity (US20190256531A1) In Vitro IV-361 has less inhibition on CDK2 (K i ≥1000 nM) or PLK1 (K i ≥5000 nM). IV-361 exhibits excellent IL-2 and IL-17 production inhibitory activity (all IC 50 ≤100 nM) in periphery blood mononuclear cell (PBMC). IV-361 exhibits excellent HCT-116 cell growth inhibitory activity (GI 50 ≤100 nM). MCE has not independently confirmed the accuracy of these methods. They are for reference only. In Vivo IV-361 (25 mg/kg/day; orally) exhibits 46% or more rate of suppression of tumor volume in female BALB nude mice with HCT-116 . MCE has not independently confirmed the accuracy of these methods. They are for reference only. Form:Solid IC50& Target:CDK7 ≤50 nM (Ki) CDK2 ≥1000 nM (Ki) |
| Smiles | O=C(N(C1)C(C)(C)C2=C1C(NC(C3([Si](C)(C)C)CCC3)=O)=NN2)NC4=CC(F)=CC=C4C |
|---|---|
| Molecular Weight | 457.62 |
| Solubility | DMSO : 90 mg/mL (196.67 mM; Need ultrasonic) |
|---|